中华医学杂志（英文版）2010，Vol.123Issue(22)：3299-3303,5.DOI:10.3760/cma.j.issn.0366-6999.2010.22.024
Mechanism of multidrug resistance of human small cell lung cancer cell line H446/VP
Mechanism of multidrug resistance of human small cell lung cancer cell line H446/VP
WANG Yan-ling 1YAN Yun-li 1ZHOU Na-jing 1HAN Shuo 1ZHAO Jun-xia 1CAO Cui-li 1Lü Yu-hong1
作者信息
摘要
Abstract
Background Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. This study aimed to investigate the mechanism of human small cell lung cancer cell line resistance to etoposide (VP-16), H446/VP.Methods The cell viability was measured by M∏ assay. Immunocytochemistry, reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting methods were used to detect the multidrug resistance gene (MDR1), bcl-2, bax and the topoisomerase Ⅱ (Topo Ⅱ) expressions in H446 and H446/VP cells after treated with or without VP-16.Results The 50% inhibition concentration (IC50) of VP-16 on H446 cells was 49 mg/L, and 836 mg/L was for H446/VP cells. The expressions of MDR1 and bcl-2 were up-regulated, while the amounts of bax and Topo Ⅱ were reduced in H446/VP cells. After treated with 49 mg/L of VP-16, it showed that the drug could significantly inhibit bcl-2 and Topo Ⅱ expressions, and increase bax expression in H446 cells compared with that of H446/VP cells.Conclusions The H446/VP cell was stably resistant to VP-16. The decreased expression of Topo Ⅱ was correlated with the H446/VP multidrug resistance. The elevated expressions of MDR1, and the altered apoptotic pathways also played an important role in VP-16 induced multidrug resistance of SCLC.关键词
small cell lung cancer/etoposide/topoisomerase Ⅱ/multidrug resistanceKey words
small cell lung cancer/etoposide/topoisomerase Ⅱ/multidrug resistance分类
医药卫生引用本文复制引用
WANG Yan-ling,YAN Yun-li,ZHOU Na-jing,HAN Shuo,ZHAO Jun-xia,CAO Cui-li,Lü Yu-hong..Mechanism of multidrug resistance of human small cell lung cancer cell line H446/VP[J].中华医学杂志（英文版）,2010,123(22):3299-3303,5.
